Skip to main content
Figure 2 | BMC Clinical Pathology

Figure 2

From: A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

Figure 2

Prognostic impact of Ki67 labeling index (LI) and p53 status in patients with hormone receptor-positive and HER2-negative breast cancer (n=142). A, Disease free survival curves for 98 patients with Ki67 LI-low tumors and 44 patients with Ki67 LI-high tumors. The 2 curves differ significantly (HR, 3.6; 95% CI, 1.7–7.9; log-rank P = 0.0004). B, Overall survival curves for 98 patients with Ki67 LI-low tumors and 44 patients with Ki67 LI-high tumors. The 2 curves differ significantly (HR, 4.4; 95% CI, 1.3–14.6; log-rank P = 0.0082). C, Disease-free survival curves for 122 patients with p53-negative tumors and 20 patients with p53-positive tumors. The 2 curves differ significantly (HR, 5.2; 95% CI, 2.3–11.9; log-rank P < 0.0001). D, Overall survival curves for 122 patients with p53-negative tumors and 20 patients with p53-positive tumors. The 2 curves differ significantly (HR, 5.7; 95% CI, 1.8–18.0; log-rank P = 0.0008).

Back to article page

BMC Clinical Pathology

ISSN: 1472-6890

Contact us